Key result
Diabetes linked to ~6.5-fold higher odds of poor 90-day outcome after stroke thrombolysis.
Why the study?
Early identification of patients at high risk of poor prognosis after thrombolytic therapy for acute ischemic stroke is essential for optimizing clinical management.
Cohort (n=286)
No
Odds Ratio: 6.511 (95% CI 1.667–24.605)
p-value: p=0.008
May aid risk stratification post-thrombolysis; hypothesis-generating and requires prospective validation before clinical adoption.
Early identification of patients at high risk of poor prognosis after thrombolytic therapy for acute ischemic stroke (AIS) is essential for optimizing clinical management. This study aimed to develop and internally validate a prognostic nomogram integrating clinical and laboratory variables. This retrospective study included 286 AIS patients treated with recombinant tissue plasminogen activator between January 2022 and August 2024. Patients were categorized into favorable (modified Rankin Scale ≤ 2, n = 198) and poor prognosis groups (modified Rankin Scale > 2, n = 88) based on outcomes at 90 days post-treatment. Clinical data, including demographic information, comorbidities, National Institutes of Health Stroke Scale (NIHSS) scores, and laboratory parameters (e.g., white blood cell [WBC] count, neutrophil count, and D-dimer levels), were collected. Multivariate logistic regression analysis identified independent predictors of poor prognosis. A nomogram was developed to predict prognosis, with performance evaluated through receiver operating characteristic analysis, Bootstrap resampling (n = 1000), and calibration curves. Clinical utility was assessed using decision curve analysis. Multivariate analysis identified 5 independent predictors of poor prognosis: diabetes (odds ratio [OR] = 6.511, 95% confidence interval [CI]: 1.667-24.605, P = .008), admission NIHSS score (OR = 1.354, 95% CI: 1.097-1.565, P = .001), WBC count (OR = 1.459, 95% CI: 1.114-1.786, P = .002), neutrophil count (OR = 1.402, 95% CI: 1.037-1.758, P = .022), and D-dimer level (OR = 2.088, 95% CI: 1.360-2.988, P = .001). The nomogram showed excellent discrimination (AUC = 0.896), good calibration (Hosmer-Lemeshow, P = .856), and clinical utility. Internal validation yielded a concordance index of 0.728. This retrospective study suggests that diabetes, NIHSS score, WBC count, neutrophil count, and D-dimer levels may be useful predictors of poor prognosis in thrombolysed AIS patients. A nomogram based on these factors showed good discriminative ability and clinical utility. Further prospective, multicenter validation is needed to confirm its applicability in routine practice.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) conducted a cohort in Acute ischemic stroke (n=286). Diabetes (along with NIHSS, WBC count, neutrophil count, and D-dimer) vs. Absence of these risk factors was evaluated on Poor prognosis (modified Rankin Scale > 2) at 90 days (OR 6.511, 95% CI 1.667-24.605, p=0.008). Diabetes, admission NIHSS score, WBC count, neutrophil count, and D-dimer levels were identified as independent predictors of poor 90-day prognosis in acute ischemic stroke patients undergoing thrombolytic therapy, with diabetes conferring an OR of 6.51.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: